21 December 2015
Axonics Modulation Technologies, Inc., developer of miniaturized implantable Sacral Neuromodulation technology, announced today that it has completed a $38.5 million Series B financing.
17 December 2015
Immunocore Limited, a world-leading biotechnology company developing novel T cell receptor (TCR) based biological drugs to treat cancer, viral infections and autoimmune disease, today announced that it has appointed James Sandy as Chief Development Officer and Julian Hirst as Director of Corporate Finance. These new positions will be based in Oxford, UK.
9 December 2015Creabilis completes EU FP7 project and selects two novel drug candidates for further development in atopic dermatitis and psoriasis
Creabilis, the dermatology company with an advanced targeted topical treatment in development for chronic pruritus (itch), today announces that two novel kinase inhibitor drugs for the treatment of atopic dermatitis and psoriasis, investigated with support from a European Union Seventh Framework Programme for Research (FP7) grant, have been selected for further development.
3 December 2015
Immunocore Limited, a world-leading biotechnology company developing novel T cell receptor (TCR) based biological drugs to treat cancer, viral infections and autoimmune disease, was awarded Biotech of the Year at last night’s SCRIP Awards 2015.
2 December 2015Axonics Announces Presentation of Study on Costs Savings Associated with Rechargeable Neuromodulation Devices for the Treatment of Overactive Bladder
Axonics Modulation Technologies, Inc. today announced that on Saturday, December 12, 2015, Karen L. Noblett, M.D., University of California, Riverside, will present results from an abstract titled “Cost Profile of Rechargeable vs. Non-rechargeable Neuromodulation Devices in the Treatment of Overactive Bladder Syndrome” at the North American Neuromodulation Society (NANS) Conference, December 10-13, 2015 in Las Vegas.